# A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee

> **NCT00669409** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 83 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** PF-04383119 (tanezumab)
- **DRUG:** PF-04383119 (tanezumab)
- **DRUG:** PF-04383119 (tanezumab)
- **DRUG:** PF-04383119 (tanezumab)
- **DRUG:** PF-04383119 (tanezumab)
- **DRUG:** PF-04383119 (tanezumab)

## Key facts

- **NCT ID:** NCT00669409
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-06
- **Primary completion:** 2009-12-25
- **Final completion:** 2009-12-25
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669409, "A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00669409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*